Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment source : Www.akerotx.com save search
Increased adiponectin following efruxifermin treatment is associatedwith improvements in dyslipidemia, glucose metabolism, and liver health in a 16-week, randomized, placebo-controlled trial in NASH
Published: 2021-06-25 (Crawled : 16:00) - akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.11%
H: 0.35%
C: -2.92%
treatment nash liver efruxifermin trial
Correlation between changes in liver fat content and improvements in serum markers of liver injury, fibrosis, and metabolism, and in histologic parameters following treatment with efruxifermin
Published: 2021-06-21 (Crawled : 13:00) - akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.73%
H: 0.23%
C: -2.29%
treatment fibrosis correlation liver efruxifermin
The role of reduction in liver fat content (MRI-PDFF) and ALT in predicting treatment response in NASH: A secondary analysis of the randomized, controlled BALANCED trial
Published: 2021-06-21 (Crawled : 12:15) - akerotx.com
AKRO | $20.23 -3.67% -3.81% 580K
|
Health Technology
|
| O: 0.73%
H: 0.23%
C: -2.29%
treatment nash liver trial
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.